These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Technetium-99m-sestamibi scintigraphy in multiple myeloma and related gammopathies: a useful tool for the identification and follow-up of myeloma bone disease. Balleari E, Villa G, Garrè S, Ghirlanda P, Agnese G, Carletto M, Clavio M, Ferrando F, Gobbi M, Mariani G, Ghio R. Haematologica; 2001 Jan; 86(1):78-84. PubMed ID: 11146575 [Abstract] [Full Text] [Related]
5. BaselinTc99-MIBI scanning predicts survival in multiple myeloma and helps to differentiate this disease from monoclonal gammopathy of unknown significance. Martín MG, Romero Colás MS, Dourdil Sahún MV, Olave P, Alba PR, Banzo JB. Haematologica; 2005 Aug; 90(8):1141-3. PubMed ID: 16079119 [Abstract] [Full Text] [Related]
9. Urinary N-telopeptide levels in multiple myeloma patients, correlation with Tc-99m-sestaMIBI scintigraphy and other biochemical markers of disease activity. Alexandrakis MG, Kyriakou DS, Passam FH, Malliaraki N, Vlachonikolis IG, Karkavitsas N. Hematol Oncol; 2003 Mar; 21(1):17-24. PubMed ID: 12605419 [Abstract] [Full Text] [Related]
10. [18F-FDG PET/CT and 99mTc-MIBI scintigraphy in evaluation of patients with multiple myeloma and monoclonal gammopathy of unknown significance: comparison of methods]. Myslivecek M, Bacovský J, Scudla V, Koranda P, Minarík J, Buriánková E, Formánek R, Zapletalová J. Klin Onkol; 2010 Mar; 23(5):325-31. PubMed ID: 21061682 [Abstract] [Full Text] [Related]
14. Technetium-99m-sestamibi scintigraphy: an alternative approach for diagnosis and follow-up of active myeloma lesions after high-dose chemotherapy and autologous stem cell transplantation. Svaldi M, Tappa C, Gebert U, Bettini D, Fabris P, Franzelin F, Osele L, Mitterer M. Ann Hematol; 2001 Jul; 80(7):393-7. PubMed ID: 11529464 [Abstract] [Full Text] [Related]
15. Staging and therapy monitoring of multiple myeloma by 99mTc-sestamibi scintigraphy: a five year single center experience. Villa G, Balleari E, Carletto M, Grosso M, Clavio M, Piccardo A, Rebella L, Tommasi L, Morbelli S, Peschiera F, Gobbi M, Ghio R. J Exp Clin Cancer Res; 2005 Sep; 24(3):355-61. PubMed ID: 16270521 [Abstract] [Full Text] [Related]
17. Technetium-99m sestamibi scintigraphy is sensitive and specific for the staging and the follow-up of patients with multiple myeloma: a multicentre study on 397 scans. Mele A, Offidani M, Visani G, Marconi M, Cambioli F, Nonni M, Catarini M, Brianzoni E, Berbellini A, Ascoli G, Brunori M, Agostini V, Corvatta L, Isidori A, Spinelli A, Gradari M, Leoni P. Br J Haematol; 2007 Mar; 136(5):729-35. PubMed ID: 17233770 [Abstract] [Full Text] [Related]
18. Bone marrow uptake of 99mTc-MIBI in patients with multiple myeloma. Fonti R, Del Vecchio S, Zannetti A, De Renzo A, Di Gennaro F, Catalano L, Califano C, Pace L, Rotoli B, Salvatore M. Eur J Nucl Med; 2001 Feb; 28(2):214-20. PubMed ID: 11303893 [Abstract] [Full Text] [Related]